Organon & Co. (NYSE:OGN) Shares Sold by Clean Yield Group

Clean Yield Group decreased its position in Organon & Co. (NYSE:OGN - Free Report) by 34.9% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 186,358 shares of the company's stock after selling 100,092 shares during the period. Clean Yield Group owned 0.07% of Organon & Co. worth $2,687,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. International Assets Investment Management LLC lifted its holdings in Organon & Co. by 1,441.2% during the fourth quarter. International Assets Investment Management LLC now owns 14,595 shares of the company's stock worth $210,000 after buying an additional 13,648 shares during the period. SteelPeak Wealth LLC purchased a new stake in Organon & Co. during the fourth quarter worth $185,000. Lewis Asset Management LLC purchased a new stake in Organon & Co. during the fourth quarter worth $153,000. Ballentine Partners LLC purchased a new stake in Organon & Co. during the fourth quarter worth $239,000. Finally, State of Alaska Department of Revenue lifted its holdings in Organon & Co. by 417.8% during the fourth quarter. State of Alaska Department of Revenue now owns 157,249 shares of the company's stock worth $2,267,000 after buying an additional 126,882 shares during the period. Hedge funds and other institutional investors own 77.43% of the company's stock.

Wall Street Analyst Weigh In

Separately, The Goldman Sachs Group upped their target price on Organon & Co. from $16.00 to $18.00 and gave the stock a "neutral" rating in a report on Tuesday, February 20th.

Insider Buying and Selling

In other news, insider Kirke Weaver bought 2,720 shares of Organon & Co. stock in a transaction that occurred on Thursday, February 22nd. The stock was bought at an average price of $18.36 per share, for a total transaction of $49,939.20. Following the purchase, the insider now directly owns 15,181 shares of the company's stock, valued at approximately $278,723.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.17% of the stock is currently owned by company insiders.

Organon & Co. Stock Down 0.1 %

Shares of Organon & Co. stock traded down $0.01 during trading on Friday, reaching $17.86. The company's stock had a trading volume of 2,010,061 shares, compared to its average volume of 1,957,155. The company has a market cap of $4.57 billion, a price-to-earnings ratio of 4.47, a P/E/G ratio of 0.85 and a beta of 0.83. Organon & Co. has a 1-year low of $10.84 and a 1-year high of $24.79. The company has a 50-day simple moving average of $17.76 and a two-hundred day simple moving average of $15.59.

Organon & Co. (NYSE:OGN - Get Free Report) last posted its quarterly earnings data on Thursday, February 15th. The company reported $0.87 earnings per share for the quarter, topping analysts' consensus estimates of $0.73 by $0.14. The firm had revenue of $1.60 billion during the quarter, compared to analysts' expectations of $1.55 billion. Organon & Co. had a negative return on equity of 212.00% and a net margin of 16.33%. As a group, analysts anticipate that Organon & Co. will post 4.08 earnings per share for the current year.

Organon & Co. Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, March 14th. Investors of record on Monday, February 26th were paid a $0.28 dividend. The ex-dividend date was Friday, February 23rd. This represents a $1.12 dividend on an annualized basis and a yield of 6.27%. Organon & Co.'s dividend payout ratio (DPR) is 28.00%.

Organon & Co. Profile

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.